We retrospectively examined EGFR-mutant patients treated with atezolizumab-bevacizumab-carboplatin-paclitaxel (ABCP) therapy…in the ABCP group, the median PFS was significantly longer in the PD-L1–positive group than in the PD-L1–negative group (p = 0.047)....In EGFR-mutant patients, the efficacy of ABCP therapy was shown to be comparable to that of platinum-based chemotherapy after EGFR-TKI therapy. Notably, for PD-L1–positive patients, ABCP therapy may be expected to have a better clinical outcome than chemotherapy...